 |
|
Volume 8, Number 2 |
|
| The problem of adverse drug reactions |
Peter Rose, Editor |
One of my few recollections of the pharmacology course at medical school was being informed that one in nine hospital admissions were a direct result of the patient’s medication. It is interesting, therefore, to reflect on how many admissions to our hospitals are currently the result of adverse drug reactions. |
|
| A comparison of inpatient and community DVT management |
Roland C Aldridge, 4th Year Medical Student; Osahon A Gbinigie, 4th Year Medical Student; Catherine A Hearnshaw, 4th Year Medical Student; Graham D Johnson, 4th Year Medical Student, University of Birmingham |
Deep vein thromboses (DVTs) are common, with an estimated annual incidence of one per 1000 population in the West.1 The goal of treatment is prevention of pulmonary embolism and recurrent DVT, with the restoration of venous patency and valvular function.2,3 Approximately 1–5% of patients with a DVT of the lower limb develop fatal pulmonary emboli.4 |
|
| Fighting thromboembolism in pregnancy – BCOG, Glasgow 2004 |
Shari Barber, Independent Medical Writer |
Preventing and treating thrombosis during pregnancy remains a major challenge today, despite dramatic improvements in maternal survival overall. This statement opened a symposium entitled ‘Experience with low molecular weight heparins in pregnancy’ at the 30th British Congress of Obstetrics and Gynaecology, held in Glasgow on 7–9 July. |
|
| Thrombosis in children Part 2: therapeutic options |
Elene Psiachou-Leonard MRCP(I) MRCPCH FGHA Consultant Paediatric Haematologist, Children’s Hospital, Leicester Royal Infirmary; Denise O’Shaughnessy FRCP FRCPath DPhil MBA Consultant Haematologist, Senior Medical Officer, Blood Policy Unit, Department of Health, London |
In the second of our two articles on thrombosis in children, we will discuss the therapeutic options for primary or secondary thromboembolic disease (TED) in neonates and children. The treatment strategy is highly individualised in paediatric patients because of the current lack of appropriate and large clinical trials.1 |
|
| Travel and thrombosis: advice to patients |
Caroline Baglin RGN Thrombophilia clinical nurse specialist, Addenbrooke’s NHS Trust, Cambridge |
The risk of blood clots triggered by travel and thrombosis has been given several different names over the last few years. It is now appropriately described as ‘traveller’s thrombosis’ instead of ‘economy class syndrome’; as thrombosis attributable to prolonged immobility also occurs in association with long-distance car, bus, rail and air travel. The longer the length of travel, the greater the risk. |
|
